Global Primary Angle-Closure Glaucoma Market, By Disease Type (Acute Angle-Closure Glaucoma and Chronic Angle-Closure Glaucoma), Type (Diagnosis and Treatment), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Retail Sales and Others) - Industry Trends and Forecast to 2031.
Primary Angle-Closure Glaucoma Market Analysis and Size
The global primary angle-closure glaucoma market addresses the rising incidence of primary angle-closure glaucoma worldwide. This market encompasses pharmaceuticals, surgical interventions, and diagnostic tools aimed at managing and treating this sight-threatening condition. Innovations in medication and surgical techniques within this market contribute to improved patient outcomes, emphasizing the importance of early detection and intervention to prevent vision loss associated with primary angle-closure glaucoma.
Data Bridge Market Research analyses the global primary angle-closure glaucoma market, which was USD 253.48 million in 2023, is expected to reach USD 407.07 million by 2031, at a CAGR of 6.1% during the forecast period 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Primary Angle-Closure Glaucoma Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024-2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Acute Angle-Closure Glaucoma and Chronic Angle-Closure Glaucoma), Type (Diagnosis and Treatment), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Retail Sales and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Egypt, Saudi Arabia, Israel, U.A.E., Kuwait, Rest of Middle East and Africa
|
|
Market Players Covered
|
Johnson & Johnson Vision Care, Inc. (U.S.), Aurolab (India), New World Medical, Inc. (U.S.), Sight Sciences (U.S.), NIDEK CO., LTD (Japan), BVI (U.S.), MicroSurgical Technology (U.S.), Bausch + Lomb (U.S.), Oertli Instrumente AG (Switzerland), Medisonic Equipments Pvt. Ltd. (India), Omni Lens Pvt. Ltd. (U.S.), Appasamy Associates Private Limited (India), NOVAEYE MEDICAL (Australia), ZEISS Group (Germany), Alcon Inc. (Switzerland), LIGHTMED (Taiwan), Reichert, Inc. (U.S.), NewVision Softcom & Consultancy Pvt. Ltd
|
|
Market Opportunities
|
|
Market Definition
Primary angle-closure glaucoma is a type of glaucoma characterized by the gradual or sudden blockage of the drainage angle within the eye, leading to impaired fluid drainage and increased intraocular pressure. This elevated pressure can damage the optic nerve, resulting in vision loss. Symptoms may include severe eye pain, headache, blurred vision, and nausea. Timely diagnosis and intervention are crucial to prevent irreversible vision impairment, often requiring medical or surgical interventions to alleviate intraocular pressure and manage the condition.
Global Primary Angle-Closure Glaucoma Market Dynamics
Drivers
- Increased Awareness among the Aging Population
The aging population is more susceptible to glaucoma, including primary angle-closure glaucoma. With a global rise in life expectancy, there is an expanding number of individuals at risk. This demographic shift creates an opportunity for the market to cater to the increasing demand for glaucoma diagnostics, monitoring, and treatment options. Heightened awareness campaigns about eye health and regular screenings contribute to early detection and treatment, providing a fertile ground for market growth.
- Growing Incidence of Diabetes and Hypertension Develops the Risk of Glaucoma
Diabetes and hypertension are known risk factors for glaucoma, including primary angle-closure glaucoma. With the global surge in the prevalence of diabetes and hypertension, there is a corresponding increase in the number of individuals at risk of developing glaucoma. This rising patient number contributes to the expansion of the primary angle-closure glaucoma market as healthcare providers focus on addressing the ocular health needs of this demographic.
Opportunities
- Market Expansion Enhances Awareness among the Population
Opportunities lie in expanding the market globally, especially in regions with high prevalence rates of primary angle-closure glaucoma. Companies that focus on establishing a strong presence in emerging markets and collaborating with healthcare providers to enhance awareness and accessibility provides the new patient populations. The potential for substantial market growth and improved patient outcomes by addressing the unmet needs in these regions.
- Personalized Medicine for Targeted Therapies
The trend towards personalized medicine presents an opportunity for the primary angle-closure glaucoma market. Tailoring treatment approaches based on individual patient characteristics, genetic factors, and disease progression can enhance the effectiveness of interventions. Companies investing in research to develop targeted therapies and precision medicine solutions for primary angle-closure glaucoma may gain a competitive edge in providing more efficient and personalized care, driving advancements in the field.
Restraints/Challenges
- Consumers Facing Challenges in Affordability
Accessibility to advanced diagnostic tools and treatment options, coupled with financial constraints in some regions, can pose a significant restraint on the primary angle-closure glaucoma market. Patients in certain areas may face challenges in accessing specialized eye care services or affording expensive glaucoma medications or surgical interventions, limiting the market's growth potential in those regions.
- Tolerability of Medications among Consumers
The global primary angle-closure glaucoma market is associated with the potential adverse effects and tolerability issues related to medications commonly prescribed for managing intraocular pressure. Some patients may experience side effects that affect their quality of life or necessitate changes in treatment plans. These challenges in medication tolerability can lead to non-compliance and discontinuation, impacting the overall effectiveness of treatment strategies and potentially hindering market growth.
This global primary angle-closure glaucoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global primary angle-closure glaucoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In December 21, Aerie Pharmaceuticals collaborated with Santen Pharmaceuticals, announced in December 2021, focuses on the development and marketing of glaucoma therapy products, including Rhopressa/Rhokiinsa and Rocklatan/Roclanda. This collaboration aims to strengthen both companies' market presence in regions such as India, Europe, Oceania, China, and parts of Latin America, fostering a global expansion of their glaucoma treatment offerings
- In March 2021, Teva Pharmaceuticals bolstered its product portfolio by introducing the first generic version of AZOPT (brinzolamide ophthalmic suspension) 1 percent in the U.S. This move enhances Teva's capabilities in addressing open-angle glaucoma and ocular hypertension, contributing to its position in the pharmaceutical market for ocular conditions
- In June 2020, Johnson & Johnson Vision Care, Inc. demonstrated its commitment to supporting eye care during the COVID-19 pandemic by announcing a generous donation of USD 0.30 million. The funds were allocated to Optometry Cares – The American Optometric Association (AOA) Foundation and the American Academy of Optometry Foundation. This donation aimed to assist practitioners in their efforts to provide essential eye care services to communities affected by the pandemic, underscoring the company's dedication to promoting eye health during challenging times
Global Primary Angle-Closure Glaucoma Market Scope
The global primary angle-closure glaucoma market is segmented on the basis of the disease type, type, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Disease Type
- Acute Angle-Closure Glaucoma
- Chronic Angle-Closure Glaucoma
Type
- Diagnosis
- Treatment
End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centres
- Others
Distribution Channel
- Direct Tender
- Retail Sales
- Others
Global Primary Angle-Closure Glaucoma Market Regional Analysis/Insights
The global primary angle-closure glaucoma market is analysed and market size information is provided by the country, disease type, type, end user and distribution channel as referenced above.
The countries covered in the global primary angle-closure glaucoma market report are the U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, South Africa, Egypt, Saudi Arabia, Israel, U.A.E., Kuwait and rest of Middle East and Africa.
North America is expected to dominate the primary angle-closure glaucoma market, primarily attributed to its status as the largest consumer market with a robust GDP. The U.S., boasting the highest household spending globally, emerges as a key player. The region exhibits elevated rates in both the diagnosis and treatment segments, solidifying its position as the primary market for products related to primary angle-closure glaucoma.
Europe is expected to experience the highest CAGR in the forecasted period, attributed to extensive research initiatives underway in Germany. The region benefits from advanced healthcare infrastructure, particularly in the diagnosis segment, enhancing its growth potential. With a robust foundation for medical studies and superior healthcare facilities, Europe stands as a key hub for advancements in the healthcare sector, contributing to anticipated growth in the coming years.
The Asia-Pacific is expected to experience significant growth, driven by shifting lifestyles and increasing urbanization. Japan, a global leader, is anticipated to dominate the market within the region due to a substantial rise in product usage and diagnosis rates, particularly in the context of primary angle-closure glaucoma. The rapid increase in awareness regarding this condition further contributes to Japan's prominence in the market, positioning it as a key player in the evolving landscape of eye care in the Asia-Pacific.
The Middle East and Africa region are expected to experience significant growth from 2024-2031, driven by a substantial increase in awareness about the target disease within these countries. The forecasted growth is attributed to the rising consciousness and understanding of the particular ailment in the region. This increased awareness is likely to contribute to higher demand for healthcare solutions, leading to the projected expansion of the pharmaceutical and healthcare sectors in the Middle East and Africa.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The global primary angle-closure glaucoma market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global primary angle-closure glaucoma market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global primary angle-closure glaucoma market. The data is available for historic period 2016-2021.
Competitive Landscape and Global Primary Angle-Closure Glaucoma Market Share Analysis
The global primary angle-closure glaucoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global primary angle-closure glaucoma market.
Some of the major players operating in the global primary angle-closure glaucoma market are:
- Johnson & Johnson Vision Care, Inc. (U.S.)
- Aurolab (India)
- New World Medical, Inc. (U.S.)
- Sight Sciences (U.S.)
- NIDEK CO., LTD (Japan)
- BVI (U.S.)
- MicroSurgical Technology (U.S.)
- Bausch + Lomb (U.S.)
- Oertli Instrumente AG (Switzerland)
- Medisonic Equipments Pvt. Ltd. (India)
- Omni Lens Pvt. Ltd. (U.S.)
- Appasamy Associates Private Limited (India)
- NOVAEYE MEDICAL (Australia)
- ZEISS Group (Germany)
- Alcon Inc. (Switzerland)
- LIGHTMED (Taiwan)
- Reichert, Inc. (U.S.)
- NewVision Softcom & Consultancy Pvt. Ltd (India)
SKU-